Mike Kratky
Stock Analyst at Leerink Partners
(3.40)
# 996
Out of 5,015 analysts
35
Total ratings
45.45%
Success rate
30.6%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $95.41 | +34.16% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $75.17 | +29.04% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $95.45 | +15.24% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $21.03 | +33.14% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $11.47 | +4.62% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $65.12 | +33.60% | 2 | Oct 25, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $260.49 | +0.96% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $14.00 | +221.43% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $10.28 | +114.01% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $314.52 | -41.50% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $31.85 | +31.87% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $429.59 | -20.39% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $73.94 | +1.43% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $32.92 | +12.39% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $15.99 | -43.71% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $12.66 | +294.94% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.47 | +2,961.22% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $429.60 | -26.68% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $57.21 | -45.81% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $17.03 | -17.79% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $20.99 | +90.57% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $26.79 | +1,333.37% | 1 | Aug 11, 2022 |
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $95.41
Upside: +34.16%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $75.17
Upside: +29.04%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $95.45
Upside: +15.24%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $21.03
Upside: +33.14%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $11.47
Upside: +4.62%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $65.12
Upside: +33.60%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $260.49
Upside: +0.96%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $14.00
Upside: +221.43%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $10.28
Upside: +114.01%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $314.52
Upside: -41.50%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $31.85
Upside: +31.87%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $429.59
Upside: -20.39%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $73.94
Upside: +1.43%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $32.92
Upside: +12.39%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $15.99
Upside: -43.71%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $12.66
Upside: +294.94%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.47
Upside: +2,961.22%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $429.60
Upside: -26.68%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $57.21
Upside: -45.81%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $17.03
Upside: -17.79%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $20.99
Upside: +90.57%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $26.79
Upside: +1,333.37%